annb0t
Top 20
Travere Therapeutics, Inc.
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for ...
>>> Read more: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for ...
>>> Read more: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
